Roche Holdings AG Basel (OTCMKTS:RHHBY) and ZALANDO SE/ADR (OTCMKTS:ZLNDY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Institutional and Insider Ownership

0.3% of Roche Holdings AG Basel shares are owned by institutional investors. Comparatively, 0.0% of ZALANDO SE/ADR shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Roche Holdings AG Basel and ZALANDO SE/ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Roche Holdings AG Basel N/A N/A N/A
ZALANDO SE/ADR 1.74% 5.78% 2.91%

Valuation & Earnings

This table compares Roche Holdings AG Basel and ZALANDO SE/ADR’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Roche Holdings AG Basel $54.15 billion 3.90 $8.77 billion $1.95 15.89
ZALANDO SE/ADR $5.07 billion 1.52 $116.64 million $0.23 67.48

Roche Holdings AG Basel has higher revenue and earnings than ZALANDO SE/ADR. Roche Holdings AG Basel is trading at a lower price-to-earnings ratio than ZALANDO SE/ADR, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Roche Holdings AG Basel has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, ZALANDO SE/ADR has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Dividends

Roche Holdings AG Basel pays an annual dividend of $0.89 per share and has a dividend yield of 2.9%. ZALANDO SE/ADR does not pay a dividend. Roche Holdings AG Basel pays out 45.6% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Roche Holdings AG Basel and ZALANDO SE/ADR, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roche Holdings AG Basel 3 3 4 0 2.10
ZALANDO SE/ADR 0 0 0 0 N/A

Roche Holdings AG Basel currently has a consensus target price of $34.00, indicating a potential upside of 9.75%. Given Roche Holdings AG Basel’s higher possible upside, analysts clearly believe Roche Holdings AG Basel is more favorable than ZALANDO SE/ADR.

Summary

Roche Holdings AG Basel beats ZALANDO SE/ADR on 8 of the 14 factors compared between the two stocks.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases. The company provides diagnostic solutions, such as blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring; diabetes therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogeneous immuno assays; immunology; infectious diseases; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control service; real-time PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. Roche Holding AG has a strategic alliance with Wisconsin Diagnostic Laboratories; and collaboration agreements with Five Prime Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and SQZ Biotechnologies Company. The company was founded in 1896 and is headquartered in Basel, Switzerland.

ZALANDO SE/ADR Company Profile

Zalando SE operates as an online fashion retailer in Europe. The company offers a range of products, including clothes, shoes, and accessories for women, men, and children. Zalando SE also sells its products through its Zalando Lounge; and brick-and-mortar stores in Berlin, Frankfurt am main, and Cologne. Zalando SE was founded in 2008 and is headquartered in Berlin, Germany.

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.